Please login to the form below
Fasenra
This page shows the latest Fasenra news and features for those working in and with pharma, biotech and healthcare.
Tecentriq’s triple negative breast cancer use among key CHMP nods
The company also received a positive opinion for a new self-administration option for Fasenra (benralizumab) via a pre-filled, single-use auto-injector, rivalling similar moves from GSK and its
Latest news
-
GSK’s Nucala gets boost with self-administration approval
it. This still leaves it at a disadvantage to Fasenra, which is administered just once every eight weeks. ... This bad news has been tempered by disappointing results for AZ's rival Fasenra in the same setting.
-
Sanofi's Dupixent gains asthma approval in Europe
This puts it into direct competition with some established players in that field, GSK's Nucala and AstraZeneca's Fasenra..
-
AZ says dropping MedImmune will help ‘streamline’ its R&D
The Gaithersburg, Maryland-headquartered company is the source of a chunk of AZ’s biologics pipeline, including cancer immunotherapy Imfinzi (durvalumab) and severe asthma drug Fasenra (benralizumab) that were both highlighted
-
Cancer drugs and China sustain AZ’s return to growth
Among these, severe asthma therapy Fasenra (benralizumab) shrugged off a tough competitive environment to post $297m in sales in its first full-year on the market despite going toe-to-toe
-
AstraZeneca wins NICE backing for asthma injection
NICE hails 'competitive pharma market'
More from news
Approximately 6 fully matching, plus 15 partially matching documents found.
Latest Intelligence
-
AstraZeneca: building a new ‘open innovation’ pharma company
AstraZeneca launched five significant new medicines in 2017: immunotherapy Iminzi, Calquence for mantle cell lymphoma, Qtern in type 2 diabetes, Bevespi Aerosphere in COPD and Fasenra for severe asthma.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
Immunocore names new CEO, Nanoform adds to commercial team and Verona hires CMO
Since joining MedImmune in 2006, Bahija has overseen the development of several new medicines, including Imfinzi, Fasenra, Lumoxiti, Siliq and FluMist Quadrivalent.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
- Senior Account Executive – Account Manager – Healthcare Advertis...
-
£32000 - £43000 Bonus Benfits
- FREELANCE Account Director – Healthcare Advertising – London – 3...
-
Competitive Daily Rates
-
Account Director – UK Office
-
Excellent salary and benefits
- Account Director, Healthcare Communications
-
Salary TBC
Subscribe to our email news alerts
- Finch Therapeutics bags $53m for microbiome therapies
- MSD taps Austria’s Themis to bolster vaccine pipeline
- Early ‘no’ for GW Pharma’s epilepsy drug, but NICE vows to collaborate
- GSK preps filings for BCMA-targeting multiple myeloma drug
- Behaviour change – is there something missing?
- NICE’s long-serving chief exec Sir Andrew Dillon to step down
PMHub
Frontera Group
Welcome to Frontera Group where our agencies immerse you in the world of the patient...
Latest intelligence
- Empowered patients: shaking the foundations of healthcare
- Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
- A uniquely English genomic medicine service
- The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
- Blended Intelligence
- Data is the most valued commodity of the modern world. For P&P it's all about the application....
Quick links
Infographics
